We recently published our article Top 5 Healthcare Stocks to Buy With $1000 in 2026. To read the full article, head on to Top 10 Healthcare Stocks to Buy With $1000 in 2026. In this piece, we take a closer look at Merck & Co. Inc. (NYSE:MRK) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Healthcare stocks are once again moving higher on investors’ watchlists as Wall Street searches for opportunities beyond the usual technology and artificial intelligence leaders. The sector has traditionally been viewed as a defensive corner of the stock market, but in 2026, the healthcare investment story is becoming much broader.

The basic defensive argument remains easy to understand. Consumers can postpone buying a new phone, cancel a vacation or reduce discretionary spending during an economic slowdown, but they generally cannot simply stop purchasing essential medications or delay every necessary medical procedure. Healthcare demand tends to remain relatively resilient even during uncertain economic periods, making healthcare stocks attractive to investors looking for stability.

But stability is only part of the story.

Artificial intelligence, an aging U.S. population, rising healthcare spending, pharmaceutical innovation and booming demand for GLP-1 obesity drugs are creating significant long-term growth opportunities across the healthcare sector. According to projections cited by the Centers for Medicare and Medicaid Services, U.S. healthcare spending is expected to grow at an average annual rate of 5.4% through 2034.

That means trillions of dollars will continue flowing through pharmaceutical companies, healthcare providers, medical-device manufacturers, biotechnology companies, insurers and other businesses connected to the healthcare industry.

For investors looking for the best healthcare stocks to buy in 2026, the opportunity may increasingly come from companies combining defensive characteristics with strong long-term growth potential.

Aging Americans Could Keep Healthcare Demand Growing

One of healthcare’s biggest advantages is also one of its most predictable: demographics.

The baby boomer generation continues to age, creating increasing demand for medications, diagnostic testing, chronic disease management, medical devices and hospital procedures. Older populations typically consume significantly more healthcare services than younger populations, giving the industry a demographic tailwind that could last for years.

Unlike many Wall Street trends that appear suddenly and disappear just as quickly, population aging happens gradually and predictably.

That matters for long-term investors.

Healthcare companies positioned in areas such as oncology, cardiovascular disease, diabetes, obesity, immunology and other age-related conditions could continue benefiting as healthcare utilization expands.

Add rising medical spending and scientific innovation, and the best healthcare stocks for 2026 may offer considerably more growth potential than their reputation as merely defensive investments suggests.

GLP-1 Drugs Have Changed the Healthcare Investment Story

Few pharmaceutical developments have attracted as much investor attention in recent years as GLP-1 medications.

Originally associated primarily with diabetes treatment, GLP-1 drugs have rapidly expanded into the obesity market, creating what could eventually become one of the largest pharmaceutical opportunities in the world.

The market is enormous.

Millions of patients potentially qualify for obesity or diabetes treatments, and pharmaceutical companies are racing to develop newer drugs that could deliver better results, easier dosing or fewer side effects.

For investors searching for pharmaceutical stocks to buy, obesity drugs have therefore become one of the most important healthcare growth themes to watch.

But the opportunity extends beyond whichever company currently sells the most popular treatment. Investors must also consider drug pipelines, manufacturing capacity, competition, regulatory approvals and potential expansion into additional medical conditions.

In other words, the GLP-1 story is only beginning to develop.

Artificial Intelligence Could Become Healthcare’s Next Major Catalyst

Artificial intelligence is another potentially powerful tailwind for healthcare stocks.

Most of the AI investment boom has centered on semiconductor companies, cloud computing providers and major technology stocks, but healthcare could become one of the technology’s most important real-world applications.

Pharmaceutical companies are increasingly exploring artificial intelligence for drug discovery and clinical research. Healthcare systems can use AI to analyze patient information, streamline administrative work and improve diagnostic processes. Medical-device companies are also integrating software and advanced data analysis into their products.

Drug development remains expensive, time-consuming and risky, but even modest improvements in research efficiency could have enormous financial consequences for pharmaceutical companies.

That creates an interesting opportunity for investors looking for AI stocks outside traditional Big Tech.

Some established healthcare companies may ultimately benefit from artificial intelligence without carrying the same lofty valuations associated with many technology stocks.

Undervalued Healthcare Stocks Could Offer the Bigger Opportunity

Healthcare stocks are not automatically attractive simply because the sector is defensive.

Valuation still matters.

Pharmaceutical companies face patent expirations. Biotechnology companies can suffer major setbacks when clinical trials fail. Health insurers can experience unexpectedly high medical costs. Medical-device companies can face pricing pressure and changing demand.

Those risks are real, but they can also create investment opportunities.

When Wall Street becomes overly focused on temporary problems, strong healthcare companies can sometimes trade at valuations that underestimate their long-term earnings potential.

That is why some of the best healthcare stocks to buy are not necessarily the stocks receiving the most attention.

A company can experience slowing growth, disappointing earnings or uncertainty surrounding a major product and still remain fundamentally strong. If investors become too pessimistic, the stock can potentially become undervalued.

For value investors, that difference between market expectations and long-term fundamentals is where opportunities can emerge.

Pharmaceutical Stocks Offer More Than One Blockbuster Drug

Large pharmaceutical companies are also becoming increasingly diversified.

Many major drugmakers now operate across oncology, immunology, neuroscience, cardiovascular medicine, diabetes, obesity and rare diseases. Strategic acquisitions can strengthen those portfolios even further by adding promising treatments and expanding drug pipelines.

That diversification matters because one of the biggest risks facing pharmaceutical stocks is dependence on a small number of blockbuster products.

Eventually, patents expire.

Competition arrives.

Revenue can decline.

Companies with deeper pipelines and broader product portfolios may be better positioned to replace aging franchises and maintain long-term growth.

Strategic acquisitions have therefore become a critical part of the healthcare investment landscape. A well-timed acquisition can give a pharmaceutical company access to promising treatments and new markets, although expensive deals can also create risks when expected products fail to deliver.

For investors evaluating the best pharmaceutical stocks for 2026, management’s ability to allocate capital effectively may be almost as important as the drugs already on pharmacy shelves.

Healthcare Could Offer Both Defense and Growth

Perhaps the most interesting feature of healthcare investing in 2026 is the possibility of getting defensive characteristics and growth potential from the same sector.

Healthcare historically performs an essential economic function regardless of whether consumer confidence is rising or falling. At the same time, major innovations in obesity treatment, cancer medicine, medical technology and artificial intelligence could create new growth opportunities.

That combination is relatively unusual.

Technology stocks can deliver tremendous growth but often trade at demanding valuations. Traditional defensive stocks may provide stability but sometimes offer limited expansion potential.

Selected healthcare companies could sit somewhere between those two categories.

Many established pharmaceutical and healthcare companies also generate substantial cash flow and pay dividends, giving investors another potential source of return while waiting for new products, earnings growth or improved market sentiment.

For investors searching for defensive stocks, undervalued stocks, dividend stocks or long-term growth investments, healthcare could therefore deserve a closer look in 2026.

Why Analysts See Opportunity in Healthcare Stocks

CFRA analysts have identified several healthcare stocks they believe offer attractive upside potential in 2026.

The selections reflect a broader investment thesis that some healthcare companies may currently be valued too pessimistically relative to their future earnings potential, product pipelines and market opportunities.

Of course, healthcare investing comes with risks.

Clinical trials can fail. Regulators can reject drugs. Patent expirations can reduce revenue. Medical costs can increase. Competition can intensify quickly.

But those uncertainties are precisely what can create attractive entry points when high-quality companies fall out of favor with investors.

The key is separating companies facing temporary challenges from businesses suffering permanent deterioration.

That distinction becomes especially important when searching for undervalued healthcare stocks.

The Search for the Best Healthcare Stocks to Buy in 2026

Investors should also remember one important Wall Street lesson: a great company is not automatically a great stock at every price.

Valuation, earnings expectations, product pipelines, competitive advantages and financial strength all matter.

The best healthcare stocks to buy in 2026 may therefore include both well-known pharmaceutical giants and companies that have recently fallen out of favor with investors.

Some could benefit from rising demand for obesity drugs. Others may gain from aging demographics, strategic acquisitions, healthcare spending growth or medical innovation.

Taken together, these trends make healthcare one of the more interesting sectors to watch in 2026.

The industry remains defensive enough to attract investors worried about economic uncertainty, yet innovative enough to participate in some of the biggest long-term trends shaping modern medicine.

The following countdown examines 10 healthcare stocks that CFRA analysts believe deserve attention in 2026, including several undervalued healthcare stocks with potentially meaningful upside.

From pharmaceutical leaders and medical innovators to companies positioned around some of the fastest-growing areas of healthcare, these names show why investors searching for the best healthcare stocks to buy may want to look beyond the market’s most crowded technology trades.

CHECK THIS OUT: 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market and 10 Biotech Stocks That Could Turn Medicine Into Wall Street’s Next Gold Rush.

Our Methodology

Our ranking of the 10 best healthcare stocks to buy for 2026 is based on CFRA analyst recommendations, factoring in upside potential, valuation, financial strength, growth prospects, product pipelines and long-term industry catalysts.

Top 5 Healthcare Stocks to Buy With $1000 in 2026

3. Merck & Co. Inc. (NYSE:MRK)

Merck & Co., Inc. (NYSE: MRK) claims the No. 3 position, supported by one of the world’s most valuable cancer franchises and a growing effort to diversify beyond it.

The center of the Merck & Co., Inc. (NYSE: MRK) story remains Keytruda.

Few drugs have reshaped modern oncology as dramatically. The cancer immunotherapy has become an enormous commercial success across multiple tumor types and a critical component of the company’s earnings power.

CFRA analyst Sel Hardy projects Keytruda could generate approximately $33 billion in full-year sales in 2026, highlighting the staggering scale of the franchise.

To put that into perspective, a single pharmaceutical product generating tens of billions of dollars annually would produce more revenue than many publicly traded companies generate across their entire operations.

Keytruda is not standing still, either.

The recent European approval of the Keytruda-Padcev combination could significantly expand the addressable market and provide another commercial catalyst. Combination therapies are particularly important in oncology because cancer treatment increasingly involves using multiple mechanisms together rather than depending on one medicine in isolation.

But Merck & Co., Inc. (NYSE: MRK) also understands the danger of becoming too dependent on one blockbuster.

That is where acquisitions become important.

The acquisitions of Cidara Therapeutics and Terns Pharmaceuticals are expected to strengthen the company’s portfolio and provide greater diversification beyond Keytruda. Merck & Co., Inc. (NYSE: MRK) is also collaborating with Daiichi Sankyo, providing another potential avenue for growth.

The strategy matters because pharmaceutical investors frequently start worrying about patent expirations years before the actual loss of exclusivity occurs. Wall Street is forward-looking, and a company with a dominant blockbuster eventually has to prove it can build the next generation of products before the current franchise matures.

Merck & Co., Inc. (NYSE: MRK) is attempting to do exactly that.

CFRA has gone a step further with this stock than with most companies on the list, assigning Merck & Co., Inc. (NYSE: MRK) a “strong buy” rating and a $149 price target. Against the July 30 closing price of $129.79, that represents roughly 15% potential upside.

For investors looking for undervalued pharmaceutical stocks, oncology stocks and blue-chip healthcare stocks, Merck & Co., Inc. (NYSE: MRK) presents an interesting proposition.

The company already owns one of the strongest franchises in global oncology. The challenge is proving that Keytruda is not the final chapter.

Strategic acquisitions, international expansion, combination therapies and pipeline development suggest management is already working aggressively on the answer.

YOU MUST READ THIS: 10 Best Medicine Stocks That Could Make Investors 100% Richer

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.